Clinical trial MS201924-0022
An open-label, multicenter, phase 1b/2a study to evaluate efficacy, safety, tolerability, and pharmacokinetics of the ATR inhibitor M1774 in combination wit cemiplimab in participants with non-squamous non-small cell lung cancer that has progressed on prior anti-PD-(L)1 and platinum-based therapies
Cancers | |
---|---|
Organ | Lung |
Trial status | Trial open for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 1b |
Academic trial | Non |
Sponsor | Merck |
EudraCT Identifier | 2022-502010-85-00 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05882734 |
Last update |